Biotech · Private company
AltruBio Inc.
Track this companyFree. Adds AltruBio Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ALTB-168Phase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- ALTB-268Phase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- ALTB-268Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ALTB-268Phase 1 · Ulcerative Colitis (UC)ClinicalTrials.gov · fetched Nov 12, 2026
- Neihulizumab (ALTB-168)Phase 1 · Steroid-refractory Acute Graft-versus-Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy ParticipantsPHASE1 · COMPLETED · started Nov 17, 2025ClinicalTrials.gov NCT07350577 · fetched Nov 12, 2026
- Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to BiologicsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 4, 2023ClinicalTrials.gov NCT06109441 · fetched Nov 12, 2026
- A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy VolunteersPHASE1 · COMPLETED · started Jan 17, 2023ClinicalTrials.gov NCT05723692 · fetched Nov 12, 2026
- Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host DiseasePHASE1 · COMPLETED · started May 31, 2018ClinicalTrials.gov NCT03327857 · fetched Nov 12, 2026
- Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UCPHASE2 · TERMINATED · started May 4, 2018ClinicalTrials.gov NCT03298022 · fetched Nov 12, 2026